Avalo Therapeutics CEO Teases Q2 Top-Line Data for AVTX-009 Phase 2b HS LOTUS Trial at Conference

Avalo Therapeutics (NASDAQ: AVTX) CEO Garry Neil said the company expects to report top-line data in the second quarter from its completed Phase 2b LOTUS trial of AVTX-009 in hidradenitis suppurativa (HS), outlining what he described as operational execution milestones in 2025 and the rationale for targeting interleukin-1 beta (IL-1β) in the disease. Company focus and